- Home
- KWR
KWR
Quaker Houghton
as 01-22-2025 1:38pm EST
| Founded: | 1918 | Country: | United States |
| Employees: | N/A | City: | CONSHOHOCKEN |
| Market Cap: | N/A | IPO Year: | 1985 |
| Target Price: | $177.33 | AVG Volume (30 days): | 190.1K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.82 | EPS Growth: | 647.22 |
| 52 Week Low/High: | $124.66 - $207.83 | Next Earning Date: | 02-27-2025 |
| Revenue: | $1,862,709,000 | Revenue Growth: | -5.49% |
| Revenue Growth (this year): | -5.03% | Revenue Growth (next year): | 3.18% |
Stock Insider Trading Activity of Quaker Houghton (KWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Slinkman David | KWR | SVP - Chief Technology Officer | Nov 25 '24 | Sell | $167.80 | 1,700 | $285,260.51 | 2,825 | |
| Bijlani Jeewat | KWR | EVP, Chief Strategy Officer | Nov 22 '24 | Sell | $165.98 | 645 | $107,056.97 | 4,747 |
Latest Quaker Houghton News
KWR Breaking Stock News: Dive into KWR Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
KWR: Lowering target price to $139.00
Simply Wall St.
8 days ago
Quaker Chemical Corporation (NYSE:KWR) Shares Could Be 48% Below Their Intrinsic Value Estimate
Argus Research
a month ago
KWR: Lowering target price to $144.00
Argus Research
a month ago
KWR: Lowering target price to $155.00
Argus Research
a month ago
KWR: Lowering target price to $162.00
Simply Wall St.
2 months ago
Quaker Chemical Corporation's (NYSE:KWR) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Argus Research
2 months ago
KWR: Lowering target price to $164.00
PR Newswire
2 months ago
Quaker Houghton Announces Quarterly Dividend
Compare KWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KWR Quaker Houghton - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.